Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Corporate Update (December 2019)
14 slides from Cynata Therapeutics's corporate update, Dec 9, 2019
Slide 1: ASX Announcement: Corporate Presentation in Relation to Sepsis
ASX ANNOUNCEMENT 9 December 2019 Corporate Presentation in Relation to Sepsis For personal use only Melbourne, Australia; 9 December 2019: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has released the attached corporate presentation on sepsis and fu
Slide 2: Corporate Presentation: Sepsis
For personal use only Corporate Presentation: Sepsis Cynata Therapeutics Limited 9 December 2019
Slide 3: Important Information
Important Information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 4: Our focus
For personal use only Our focus Using our proprietary CymerusTM platform technology to develop commercially scalable cellular therapeutic products to treat serious chronic disorders www.cynata.com 3
Slide 5: What is sepsis?
What is sepsis? For personal use only Sepsis is a life-threatening condition caused by the body's response to an infection • Sepsis is also known as blood poisoning, septicaemia, or in its most severe form, septic shock • It affects ~30 million people worldwide each year, leading to up to 6 million
Slide 6: Clinical significance
Clinical significance For personal use only Enormous unmet medical need • Sepsis is the most common cause of death in hospital Intensive Care Units • Implicated in 1 in 20 deaths in the population as a whole and up to 50% of all hospital deaths • Approximately 30% of patients diagnosed with severe s
Slide 7: Cynata/RCSI Development Partnership
Cynata/RCSI Development Partnership For personal use only • The Royal College of Surgeons in Ireland is an international not-for-profit health sciences institution, founded in 1784, with its headquarters in Dublin • RCSI is ranked among the top 2% of universities worldwide and its research is ranked
Slide 8: Preclinical studies of Cymerus MSCs in sepsis – methods (1)
Preclinical studies of Cymerus MSCs in sepsis – methods (1) For personal use only In vitro studies • The ability of Cymerus MSCs to enhance phagocytosis, in comparison to bone marrow-derived MSCs (BM-MSCs) and a negative control, was assessed by co- culturing the cells with macrophages (white blood
Slide 9: Preclinical studies of Cymerus MSCs in sepsis – methods (2)
Preclinical studies of Cymerus MSCs in sepsis – methods (2) For personal use only In vivo studies • Pneumonia-induced sepsis was caused in rats by instilling E. coli into the trachea (windpipe) • Two versions of the model were used – mild and severe (the severity is adjusted by varying the dose of E
Slide 10: Preclinical studies of Cymerus MSCs in sepsis – results
Preclinical studies of Cymerus MSCs in sepsis – results In vitro studies For personal use only • Cymerus MSCs and BM-MSCs resulted in higher levels of E. coli in macrophages and a statistically significant increase in phagocytosis compared to negative controls (p<0.05) • The effects were similar in
Slide 11: Discussion
Discussion For personal use only • Particularly encouraging that Cymerus MSC treatment was most effective in the severe sepsis model, as that is where greatest unmet need lies • This finding is consistent with the known ability of MSCs to respond to their environment • Cynata considers these highly
Slide 12: Cymerus platform enables production of iPSC-derived cellular therapeutics
Our patented Cymerus platform enables the production of iPSC-derived cellular therapeutics from a single adult donor Conventional MSC processes For personal use only MSCs change when excessively Extensive MSC Cells from donors MSC isolation culture expansion expanded: loss of potency, senescence, de
Slide 13: Cymerus platform has potential applications across a wide range of diseases
Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Key advantages of the Graft vs Host Disease platform: (GvHD) Crohn’s Disease Others Scalability & Consistency Fistula Coronary Artery Disease Consistent product Potential future quality – sin
Slide 14: Contacts
For personal use only CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics +61 (0)412 119343 ross.macdonald@cynata.com Claire LaCagnina, U.S. Media Contact +1 315 765 1462 clacagnina@6degreespr.com Cynata Therapeutics Limited Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia PO Box 7165,
Cynata Therapeutics — Corporate Update (December 2019) on 6ix